Tag Archive genetic engineering

DNA-based ‘bioremediation’ could be cheaper than current treatment, researchers say

August 1, 2021 Comments Off on DNA-based ‘bioremediation’ could be cheaper than current treatment, researchers say By admin

Genetic engineering and bioengineering have been around for decades, but with advances in both technology and materials, researchers are starting to look at how they might be applied to other diseases.

A team of researchers led by Dr. John R. Anderson at the University of California, Berkeley is proposing a DNA-derived bioengineer called a “bioreactor” that could help treat a range of diseases, including cancer and autoimmune disorders.

The research team, which includes Dr. Peter S. Smith of the National Institutes of Health and Dr. Randal B. Johnson of the University at Buffalo, published their proposal in the journal ACS Nano on March 2.

“The new approach could revolutionize the way we approach many of the common cancers,” said Dr. Anderson, a senior scientist at Berkeley’s Department of Biomedical Engineering and an expert in bioengineering and genetic engineering.

“We can create new therapies from a broad set of molecules and then selectively target the genetic code that we need to deliver them,” he added.

Bioreactor could be used to treat diseases like Crohn’s disease, type 2 diabetes and Parkinson’s diseaseIn their paper, the researchers describe how they engineered a small number of proteins in a laboratory to bind to an enzyme that produces a molecule that binds to DNA.

They then isolated this enzyme, which they dubbed a “genetic biosensor,” and inserted it into cells.

The scientists then used the biosensor to create a bioengineered drug that could bind to the enzyme.

The scientists then applied their approach to three types of tumors, including colorectal cancer, osteosarcoma and multiple myeloma, all of which are characterized by an inability to make beta-catenin, a protein that is present in cells that can be used as a marker for the presence of certain genes.

“When we use the biosensors to make the drug, we can directly target genes that cause those tumors to form,” said Anderson.

“We can directly control how much beta-clin, which is a biomarker for tumor progression, we’re getting from these tumors.”

A recent study by a group of researchers published in the Proceedings of the Royal Society B also suggested that bioengineers could use the technology to create drugs that could target genes responsible for tumor growth.

“There’s a lot of work that’s being done right now to build a bioengineering platform for a wide variety of diseases and cancers, and this is a really exciting opportunity to really do that,” said co-author Dr. Martin D. Soderberg of the Institute for Advanced Medical Research.

The bioengineering approach was also an attractive choice for the researchers to apply their approach on cancer because it allows them to use a large number of materials, a larger array of genes, and a larger amount of the enzyme, compared to the other methods.

“I think it’s one of the most promising approaches for cancer biology,” said study co-leader Dr. Soren Nordgaard of the Department of Pathology at Lund University in Sweden.

Dr. Sondheim said the bioengineerers approach is a major step toward the development of bioprospecting technologies that could ultimately help diagnose cancer in humans.

“In this context, it’s also a good example of how the development and commercialization of bioengineering is still in its infancy,” he said.

“This is not a science fiction approach; it’s a real approach that is already happening,” he continued.